Albireo Receives Positive Opinion for Orphan Drug Designation for A4250 for ... MarketWatch (press release) "This designation is an important milestone in our efforts to provide a treatment for patients with cholestatic liver diseases; a disease entity often leading to severe symptoms, liver transplantation and with reduced survival. A4250 is an inhibitor of ... |
